Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

BACKGROUND: Activation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a mechanism of resistance to EGFR inhibitors. METHODS: We have investigated t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Transl Med
Auteurs principaux: Madoz-Gúrpide, Juan, Zazo, Sandra, Chamizo, Cristina, Casado, Victoria, Caramés, Cristina, Gavín, Eduardo, Cristóbal, Ion, García-Foncillas, Jesús, Rojo, Federico
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2015
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4552997/
https://ncbi.nlm.nih.gov/pubmed/26319934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0633-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires